Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 20/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 6/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 6/20 | 1.00 |
| ▸ | CCND1 | P24385 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 6/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | CCND2 | P30279 | 10/20 | 0.98 |
| ▸ | CCND3 | P30281 | 10/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.83 |
| ▸ | CDK2 | P24941 | 6/20 | 0.83 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29507600 | 1.00 | CDK4 (1.00) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL6222207 | 0.99 | CDK4 (1.00) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| Hydrochloric Acid SCHEMBL29507523 | 0.92 | CDK4 (1.00) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| Hydrochloric Acid SCHEMBL4444109 | 0.92 | CDK4 (1.00) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL4830730 | 0.92 | CDK4 (0.87) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL29507634 | 0.92 | CDK4 (0.87) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL4833348 | 0.92 | CDK4 (0.87) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL6221524 | 0.92 | CDK4 (1.00) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL4826569 | 0.91 | CDK4 (0.85) | CDK4CCND1FGFR1FGFR2FGFR4 | |
| SCHEMBL30176617 | 0.91 | CDK4 (0.85) | CDK4CCND1FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | claimed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | claimed |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111148518-A | Methods of modulating regulatory T cells and immune responses using CDK4/6 inhibitors | 丹娜法伯癌症研究院 | 2020-05-12 | — | — | CN | disclosed |
| US-20200108066-A1 | METHODS FOR MODULATING REGULATORY T CELLS AND IMMUNE RESPONSES USING CDK4/6 INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2018-09-06 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| US-20090030005-A1 | Combinations for the treatment of cancer | AMGEN INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-7456168-B2 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK4 1/4885FGFR1 386/4885FGFR3 366/4885 |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | CDK6, CDK4, CDK2 | CDK4 2/4885FGFR1 504/4885FGFR3 416/4885 |
| US-20180250400-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 Inhibitor | BTK, JAK2, CDK4 | CDK4 3/4885FGFR1 971/4885FGFR3 537/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK4 3/4885FGFR1 1178/4885FGFR3 691/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK4 1/4885FGFR1 536/4885FGFR3 416/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | CDK4 1/4885FGFR1 137/4885FGFR3 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.